Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mikrobiomik
Derio, Bizkaia (Vizcaya), Spain
- Ownership
- Private
- Development stage
- Other
01
Overview
MBK-01 demonstrated efficacy and safety in Phase III for Clostridioides difficile infection (primary/recurrence), showing promising clinical results. The company is the first to bring a microbiota-based biologic to market in the EU for this indication. Mikrobiomik is an innovative EU-based biotech/biopharma company developing GMP-grade live microbiota therapeutics for high-unmet-need GI, hepatic, infectious, and oncology indications, with MBK-01 poised as the EU’s first approved capsule-based fecal microbiota drug for Clostridioides difficile and a growing pipeline for other indications.
- Therapeutic areas
- OncologyGastroenterologyInfectious DiseasesMetabolic Disorders
- Modalities
- Live biotherapeutic product therapyMicrobial therapy (oral capsules of freeze-dried/intact fecal microbiota)
- Industry
- Biotech
02
Partnerships
Strategic alliances with multinational pharmaceuticals for commercialisation in infectious, digestive, and oncology diseases (details undisclosed)Device partnership: Logos Biosystems/Aligned Genetics, Isogen Life Science (for QUANTOM TX cell counter validation)
Beyond the preview
Go deeper on Mikrobiomik.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mikrobiomik.